NEW YORK (AVAFIN) -- Block trades serve as a useful indicator for investors trying to understand the sentiment
of large financial institutions. A total of 22 block trades were executed today,
typically at least 10,000 shares or more represent a single block unit.
Further analysis into the trading activity reveals that 255,049
shares were bought and 341,859 shares were sold. The bought/sold ratio for
shares of Bristol-Myers Squibb Company is 0.75, representing a negative net cash
flow of $3,611,283 out of the stock.
View all Block Trading Activities
On the options side, a total of total of 301,478 call and 10,435 put contracts were traded
yielding a 0.03 put/call ratio.
Bristol cut $2.5 billion in operating costs and is planning further cuts, which should help the company prepare for the difficult 2012-15 period, when patents expire on Plavix, Avapro, and Abilify.
Additionaly, Close to half of Bristol's late-stage pipeline focuses on cancer--an indication where the FDA aggressively approves drugs. Cancer drugs also carry strong pricing power.
Bristol-Myers Squibb Company is currently trading at $41.68, up $0.54 (+1.31%) in today's trading
session. The shares of the stock were trading between $41.16 and $41.79. To date, the stock has gained 1.86% within the last week.
Todays's volume of 9M shares is less than the average volume of 9M
shares. The technical momentum Relative Strength Index indicator shows overbought conditions. BMY is trading above the 50 day moving average and
higher than the 200 day moving average.
Bristol-Myers Squibb Company is a global biopharmaceutical Company, which is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis.